Skip to main content

Table 4 Lenalidomide in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dosage

Clinical trials

No.of Pts

Response

Reference

Lenalidomide

 

Relapsed

5/10/15 mg

Phase II

95

CR:2%

[34]

Refractory

ORR:79%

Lenalidomide

Dexamethasone

Untreated

5 mg

Phase II

18

CR:6%

[35]

ORR:59%

Lenalidomide

Fludarabine

Untreated

2.5 mg

Phase I/II

64

CR:11%

[36]

Rituximab

Minimally

   

ORR:63%

 
  

treated

     
  1. Abbreviations: ORR overall response rate, CR complete remission.